Additional Information
Market: TSX
Sector: Medical
EPIC: RVX
Latest Price: 0.66  (3.97% Ascending)
52-week High: 0.88
52-week Low: 0.46
Market Cap: 55.86M
1 year chart
1 day chart
Resverlogix
www.resverlogix.com
Resverlogix Corp. (Resverlogix) is a biotechnology company engaged in the discovery and development of therapies for global medical markets. It has three separate cardiovascular disease (CVD) research programs.

Resverlogix stock up over 12% after heart disease drug meets main goal of clinical study

28th Aug 2012, 11:56 am by Deborah Sterescu
The BET protein inhibitor, RVX-208, 'significantly increased' HDL-C - a good form of cholesterol - which was the primary endpoint of the trial. The BET protein inhibitor, RVX-208, "significantly increased" HDL-C - a good form of cholesterol - which was the primary endpoint of the trial.

 

Resverlogix Corp's (TSE:RVX) shares jumped Tuesday after it said its cardiovascular disease drug RVX-208 met the main goal of a phase 2b clinical study. 

The BET protein inhibitor, RVX-208, "significantly increased" HDL-C - a good form of cholesterol - which was the primary endpoint of the trial. 

Shares of the company gained 12.7 per cent to $1.77 as of 11:35am ET. 

RVX-208 is currently in clinical study for the treatment of atherosclerotic cardiovascular disease. It functions by removing atherosclerotic plaque through reverse cholesterol transport (RCT), the natural process through which this plaque is transported out of the arteries and removed from the body by the liver. 

The phase 2 study also met secondary endpoints, showing increases in levels of Apo-Al, and large HDL particles - both believed to be important factors in enhancing reverse cholesterol transport activity. 

The trial, called Sustain, was directed by a clinical steering committee chaired by Dr. Steven Nissen, with Dr. Stephen Nicholls serving as principal investigator. 

The committee has approved release of the findings pending submission of full trial results for publication in a peer-reviewed medical journal, the company said. 

"Successful completion of the SUSTAIN trial provides Resverlogix with important data regarding improvement in the functionality of the HDL produced by RVX-208," said president and CEO, Donald McCaffrey. 

"Safety data from SUSTAIN reconfirm our belief that early liver signals witnessed in this and previous trials were of a transient nature," McCaffrey added. 

"The data support that RVX-208 is suitable for chronic use. The value of this knowledge will benefit our entire epigenetic and bromodomain research program by showing safe versions of epigenetic regulating molecules are indeed achievable.

"We believe that based on the collective knowledge gained from our recent trials, our company is well positioned as we approach the key plaque regression data expected in our ongoing ASSURE trial."

The phase 2b trial was conducted in South Africa and led by investigators at the Cleveland Clinic. The study enrolled 176 patients with established atherosclerotic cardiovascular disease (CVD) and low high-density cholesterol (HDL-C). 

The primary purpose of the trial was to measure changes in HDL, Apo-AI and other lipid parameters compared with placebo, while also assessing safety over an extended treatment period.

The company noted that RVX-208 also has the potential to treat other indications, including neurodegenerative disorders.

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. 

 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here